Last reviewed · How we verify
67Cu-SAR-bisPSMA
PSMA-targeting radioligand
PSMA-targeting radioligand Used for Prostate cancer.
At a glance
| Generic name | 67Cu-SAR-bisPSMA |
|---|---|
| Sponsor | Clarity Pharmaceuticals Ltd |
| Drug class | Radioligand |
| Target | PSMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
67Cu-SAR-bisPSMA is a radioligand that targets prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer.
Approved indications
- Prostate cancer
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 67Cu-SAR-bisPSMA CI brief — competitive landscape report
- 67Cu-SAR-bisPSMA updates RSS · CI watch RSS
- Clarity Pharmaceuticals Ltd portfolio CI